Faculty Bibliography

The diagnosis of miliary tuberculosis (TB) may be a challenging task for the physician. Pancreatitis is an extremely rare presentation of miliary TB. A healthy 31-year-old American male was admitted because of severe nausea, anorexia, malaise and night sweat for 4 days. He was febrile and his physical examination was unremarkable. The chest X-ray (CXR) was normal and the computed tomographic (CT) evaluation of the abdomen was consistent with pancreatitis. On the 12th day in the hospital, he complained of dyspnea and his chest CT showed bilateral ground-glass opacities. Subsequent bronchoscopy was not diagnostic. Open lung biopsy (OLBx) revealed multiple necrotizing granulomas. The patient responded to antituberculous therapy and was discharged home 3 weeks later. Miliary TB is a curable disease, which can take many forms. A high index of clinical suspicion and diagnostic persistence are required for diagnosis. Early diagnosis and treatment of miliary TB nurtures better outcomes

Transbronchial needle aspiration is a safe procedure with a complication rate under 1%. Aseptic pericarditis and mediastinal hematoma are rare complications. We present a case of a 40-year-old patient who underwent left paratracheal lymph node biopsy with a 21-g needle who sustained both aseptic pericarditis and a mediastinal hematoma. His symptoms of pericarditis were treated with ibuprofen, whereas the hematoma resolved spontaneously.

In 1977, Cunningham et al reported a 45% risk of hemorrhage in azotemic patients undergoing flexible bronchoscopy (FB) with biopsy. There have been no recent studies evaluating renal insufficiency as a relative contraindication to biopsy. We reviewed all charts of Bellevue Hospital bronchoscopies from October 1997 to October 2002 for blood urea nitrogen (BUN), creatinine (Cr), hemogram, and coagulation studies as well as the type of biopsy performed, pretreatment medications, and complications from the FB. Patients were included if they had a BUN >=30 mg/dL and/or a Cr >=2 mg/dL. Seventy-two patients met criteria. Twenty-five of 72 (35%) patients had bronchoscopic biopsy. Seven of 25 (28%) were hemodialysis (HD) patients and 18 of 25 (72%) were nondialysis (ND) patients. All HD patients received FB within 24 hours after HD and were given desmopressin (DDAVP) prebronchoscopy. One patient with coagulopathy also received platelets and fresh-frozen plasma. Six of 7 HD patients had forceps biopsy (BX) (BUN range 31-65; Cr range 5.2-18.7) and 1 had transbronchial needle aspiration (TBNA) (BUN 32; Cr 4.3). Twelve of 18 ND patients had BX (BUN 20-69; Cr 0.9-2.5), 4 had TBNA (BUN 20-62; Cr 1.1-4.5), and 2 had BX and TBNA (BUN 30-35; Cr 1.4-1.5). One of 25 (4%) ND patients had a major complication of massive bleeding that required intervention. One of 25 (4%) ND patients had minor bleeding. There were no complications in the HD group. These findings suggest a low complication rate of bleeding in patients undergoing biopsy during FB if screened for coagulation abnormalities and, if receiving HD, done after HD with prebronchoscopy DDAVP. Our hemorrhagic complication rate was much lower than that reported in 1977. These data advocate further studies to evaluate whether bronchoscopic biopsy should be considered a relative contraindication in patients with renal insufficiency.

BACKGROUND: Asbestos bodies (AB) in BAL cells are specific markers of asbestos exposure. METHODS: We retrospectively reviewed BAL cytocentrifuge slides of 30 utility workers with a history of asbestos exposure and 30 normal volunteers. BAL cytocentrifuge slides were blinded and scanned under 40 x light microscope. RESULTS: AB were found more frequently in subjects with a history of asbestos exposure compared to normal volunteers (10 of 30 subjects, 33%, vs 0 of 30 subjects). The mean number of AB seen in the AB-positive group was 2.7 per slide. Demographic data were comparable including age, gender, and smoking. Exposure histories were also similar: duration > 20 years, onset > 30 years ago, and time since last exposure > 7 years. More AB-positive patients reported respiratory symptoms (70% vs 26%, p < 0.05). High-resolution CT scans of AB-positive patients revealed a higher prevalence of parenchymal disease (70% vs 26%, p < 0.05). AB-positive subjects had reduced pulmonary function compared to AB-negative subjects: FVC (86% vs 97% predicted), FEV(1) (77% vs 92% predicted, p < 0.05), and diffusion capacity of the lung for carbon monoxide (76% vs 104% predicted, p < 0.01). CONCLUSION: In individuals with a history of asbestos exposure, the presence of AB in BAL cells is associated with higher prevalence of parenchymal abnormalities, respiratory symptoms, and reduced pulmonary function

STUDY OBJECTIVE:s: Although pulmonary mycetoma has been well-described in immunocompetent hosts, the only description in HIV-infected patients has been of 10 patients from our institution, from 1992 to 1995. To further investigate the impact of HIV status on the presentation and course of pulmonary mycetoma, we conducted a follow-up study. DESIGN: Retrospective review of all cases of pulmonary mycetoma at Bellevue Hospital from 1992 to 1999. SETTING: Patients were evaluated on the inpatient chest service and in the outpatient chest and HIV clinics of Bellevue Hospital in New York City. PATIENTS: We identified 74 patients with pulmonary mycetoma; 20 of them were HIV-infected (27%). INTERVENTIONS: The 20 HIV-infected patients were treated with antiretroviral and/or antifungal therapy. MEASUREMENTS AND RESULTS: Predisposing diseases were pulmonary tuberculosis (TB), Pneumocystis carinii pneumonia (PCP), or both TB and PCP. Seventeen patients had a CD4+ cell count of < 100 cells/ micro L at presentation. Hemoptysis was present in 13 patients, but was massive in only 1 patient. Cough was common. Of the 18 patients for whom follow-up was available, 11 received antifungal treatment and 7 were observed without therapy. Six patients received both antiretroviral and antifungal therapy. Disease progression occurred in 50%. Only five patients exhibited radiographic or clinical improvement. All five were treated with both antiretroviral and antifungal therapy. CONCLUSIONS: PCP is a risk factor for pulmonary mycetoma in the HIV-infected individual. HIV-infected patients with mycetomas have a significant rate of disease progression, although they rarely have life-threatening hemoptysis. A combination of antifungal and antiretroviral therapy may improve the clinical outcome in HIV-infected patients with pulmonary mycetoma

The objective of this study was to evaluate the mechanisms of colchicine action in pulmonary fibrosis. The study included 10 patients with pulmonary fibrosis (idiopathic pulmonary fibrosis 5, asbestosis 4, and scleroderma 1) who had been admitted to Bellevue Hospital Center, a tertiary care public hospital in New York City. We administered colchicine 0.6 mg orally for 12 weeks to patients with pulmonary fibrosis. Symptoms, high resolution CT scans, pulmonary function tests, and bronchoalveolar lavage parameters were compared prior to and after treatment. Results showed declines in dyspnea index, selective improvement in several CT scans, but no statistically significant change in BAL cells, cytokines, fibronectin, or hydroxyproline. However, there was a decline in hydroxyproline in the BAL fluid in 8/10 patients. We concluded that colchicine has a mild antifibrotic effect which may be in inhibiting collagen formation since there was no effect on the inflammation that accompanies fibrosis

We report an illustrative case of advanced 'hut lung,' or domestically acquired particulate lung disease (DAPLD), in a recently emigrated nonsmoking Bangladeshi woman with a history of 171 hour-years of exposure to biomass smoke. She presented with symptoms of chronic cough, dyspnea, and early parenchymal lung disease. High-resolution computed tomography (CT) of the chest demonstrated numerous 2- to 3-mm nodules, sparing the pleural surface. To our knowledge, this is the first such report of CT findings in the literature. Bronchoscopy yielded typical anthracotic plaques and diffuse anthracosis with interstitial inflammation on histopathologic examination of biopsy specimens. DAPLD is potentially the largest environmentally attributable disorder in the world, with an estimated 3 billion people at risk. Caused by the inhalation of particles liberated from the combustion of biomass fuel, DAPLD results in significant morbidity from infancy to adulthood. Clinically, DAPLD manifests a broad range of disorders from chronic bronchitis and dyspnea to advanced interstitial lung disease and malignancy. While a detailed environmental history is essential for making the diagnosis in most individuals, for patients with advanced DAPLD, invasive modalities such as bronchoscopy with transbronchial biopsy and examination of bronchoalveolar lavage fluid help differentiate it from other diseases. Recognition of this syndrome and removal of the patient from the environment is the only treatment. The development of well-controlled interventional trials and the commitment of sufficient resources to educate local populaces and develop alternative fuel sources, stove designs, and ventilation are essential toward reducing the magnitude of DAPLD